Physician profile
Anjuli Kumar
NPI 1720102197
$1,576.89
in general payments reported to CMS, 2019-2025
12 companies · $512 in 2025
The $512 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $7.41 · 2021: $23.56 · 2022: $88.26 · 2023: $358 · 2024: $337 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $426.57 | 2023-2025 | Dupixent |
| Genzyme Corporation | $270.45 | 2022-2025 | |
| Alcresta Therapeutics, INC. | $160.38 | 2025 | Relizorb |
| Abbvie INC. | $159.74 | 2019-2021 | |
| Mirum Pharmaceuticals, INC. | $144.16 | 2024 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $143.02 | 2025 | Bylvay |
| Coloplast Corp | $107.00 | 2019 | |
| Novo Nordisk INC | $47.30 | 2024 | |
| Qol Medical, LLC | $36.22 | 2025 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $34.13 | 2023 | Gattex |
| Rhythm Pharmaceuticals, INC. | $27.39 | 2024 | Imcivree |
| Travere Therapeutics, INC. | $20.53 | 2019-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjuli Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.